Cervical Cancer Case Study: Staging, Treatment, and Care Plan
This paper presents a clinical case study and care plan for a 45-year-old patient recently diagnosed with cervical cancer. It reviews the epidemiology of cervical cancer, the role of human papillomavirus (HPV) as the primary causative agent, and the World Health Organization's classification of cervical cancer types. The paper walks through the staging process using the Bethesda System and available imaging modalities, then outlines treatment options—including surgery, radiation therapy, and chemoradiotherapy—matched to disease stage. Long-term management considerations such as post-treatment monitoring, vaginal stenosis prevention, and complication profiles are addressed, followed by a discussion of prognosis and five-year survival rates by stage.
- Introduction to Cervical Cancer: Epidemiology, HPV causation, and cancer type classification
- Staging the Disease: Bethesda System, imaging tools, and stage definitions
- Treatment Plan: Surgery, radiation, and chemoradiotherapy options by stage
- Long-Term Management: Post-treatment morbidity, monitoring schedule, and follow-up
- Prognosis: Stage-specific recurrence risk and five-year survival rates
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper moves logically from diagnosis to staging to treatment to long-term follow-up, mirroring actual clinical workflow and making it easy for a patient or student to follow the care continuum.
- It grounds each recommendation in cited clinical trials and authoritative guidelines (NCI, ACR Appropriateness Criteria), lending credibility to the treatment comparisons it presents.
- Specific drug names, staging sub-categories, and quantified survival statistics (e.g., 50–60% five-year survival for late-stage disease) give the paper concrete clinical detail rather than vague generalizations.
Key academic technique demonstrated
The paper demonstrates evidence-based synthesis: rather than simply listing treatment options, it cites clinical trial outcomes to compare surgery versus radiation therapy and to justify chemotherapy drug selection. This technique—anchoring clinical recommendations to primary research and guideline sources—is a hallmark of health-sciences writing at the graduate level.
Structure breakdown
The paper opens with an epidemiological overview and HPV context, then dedicates a detailed section to the staging taxonomy (Stages 0–IVB). A Treatment Plan section matches imaging, surgical, and chemoradiotherapy options to disease stage. Long-Term Management addresses post-treatment morbidity comparisons and follow-up schedules. The Prognosis section closes with stage-specific recurrence risks and survival rates, reinforcing the importance of early screening.
Introduction to Cervical Cancer
The following represents a plan of care, including information intended to educate a patient about what she can expect following a recent diagnosis of cervical cancer at the age of 45. The good news is that a cervical cancer diagnosis is no longer a death sentence.
Cervical cancer is common and afflicts close to 530,000 women worldwide each year (Colombo et al., 2012). Importantly, human papillomavirus (HPV) infections are believed to be the most important causative agent; this virus is detected in 99% of all cervical tumors. Accordingly, the expected protection rate conferred by the HPV vaccine is around 70%.
Of the three categories of cervical cancer recognized by the World Health Organization (WHO), squamous cell carcinoma is by far the most common, representing 70–80% of all cervical cancers (Colombo et al., 2013). Other types include glandular (adenocarcinoma), neuroendocrine, undifferentiated, and mixed. The type of cancer is important because it affects prognosis and the plan of care, in addition to how advanced the disease is (stage), tumor size, patient age, and overall patient health (NCI, 2013).
Staging the Disease
Once cervical cancer has been diagnosed, the first step is to stage the cancer (NCI, 2013). Of primary concern is whether the tumor is localized within the cervix, involves the whole cervix, or has spread to surrounding tissues and lymph nodes. The Bethesda System for cervical cytology classification helps initiate this process by providing terminology standards for specimen quality, cancer type, and grade of lesion (Davey, 2003). A number of imaging tools are also available to help determine the extent of cancer spread within the cervix, surrounding tissue, and the rest of the body if metastatic disease is suspected (NCI, 2013).
Stage 0 is used to categorize microscopic tumors confined to the innermost lining of the cervix (NCI, 2013). Stage I tumors are also confined to the cervix but are larger and have invaded cervical tissue. The main difference between stages IA1, IA2, IB1, and IB2 is size, with the last stage in this sequence representing tumors large enough to be seen without a microscope and involving the entire cervix.
Stage II tumors have spread beyond the cervix into surrounding tissues. Stage IIA cervical tumors have involved the upper two-thirds of the vagina but not the uterus or surrounding tissues, while stage IIB has involved the tissues around the uterus. The difference between stages IIA1 and IIA2 is also mainly size. Stage III represents tumors that have involved most of the vagina, the pelvic wall, and/or compromised kidney function. The difference between stages IIIA and IIIB is the degree to which the tumor has spread, with stage IIIB representing pelvic involvement extensive enough to compromise ureter function. If the bladder and/or rectum are also involved, the cancer is classified as stage IVA; if the cancer has spread to regions of the body far from the pelvic region, it is considered stage IVB.
References
Colombo, N., Carinelli, S., Colombo, A., Marini, C., Rollo, D., and Sessa, C. (2012). Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 23(suppl. 7), vi27–vi32.
Davey, D. D. (2003). Cervical cytology classification and the Bethesda System. Cancer Journal, 9(5), 327–335.
NCI (National Cancer Institute). (2013). Cervical cancer treatment (PDQ). Cancer.gov. Retrieved November 9, 2013, from http://www.cancer.gov/cancertopics/pdq/treatment/cervical/Patient/page1/AllPages/Print.
Querleu, D. and Morrow, C. P. (2008). Classification of radical hysterectomy. Lancet Oncology, 9, 297–303.
Small, W. Jr., Strauss, J. B., Jhingran, A., Yashar, C. M., Cardenes, H. R., Erickson-Wittmann, B. A. et al. (2012). ACR Appropriateness Criteria definitive therapy for early-stage cervical cancer. American Journal of Clinical Oncology, 35, 399–405.
Wolfson, A. H., Varia, M. A., Moore, D., Rao, G. G., Gaffney, D. K., Erickson-Wittmann, B. A. et al. (2012). ACR Appropriateness Criteria: role of adjuvant therapy in the management of early-stage cervical cancer. Gynecologic Oncology, 125, 256–262.
Create your account
Always verify citation format against your institution’s current style guide requirements.